Company / Net Income
Celldex Therapeutics, Inc. Net Income History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$258.8M
FY2025
5-year range
-$258.8M / -$141.4M
FY2023-FY2025
Trend
-63.9%
vs FY2024
Sector context
#147 of 163
Health Care
What the data says
Among 163 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 10% for net income. Declined from -$141M to -$259M over the past 2 years.
Based on SEC 10-K filings.
-$259M in FY2025.
Declined from -$141M to -$259M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 163This company -$258.8M Sector average $467.8M
▼
-155.3% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 63.9% year-over-year.
- Ranks #147 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$258.8M | -63.9% |
| FY2024 | -$157.9M | -11.6% |
| FY2023 | -$141.4M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026